Bristol-Myers Squibb Company, commonly referred to as BMS, is a leading global biopharmaceutical firm headquartered in the United States. Founded in 1887, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative medicines in oncology, immunology, and cardiovascular disease. BMS is renowned for its groundbreaking therapies, such as Opdivo and Eliquis, which have transformed treatment paradigms and improved patient outcomes. The company’s commitment to research and development has positioned it as a key player in the pharmaceutical industry, consistently achieving significant milestones, including numerous FDA approvals and recognitions for its contributions to healthcare. With a robust pipeline and a dedication to addressing unmet medical needs, Bristol-Myers Squibb continues to solidify its market position as a pioneer in biopharmaceutical innovation.
How does Bristol-Myers Squibb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bristol-Myers Squibb's score of 74 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Bristol-Myers Squibb (BMS) reported total greenhouse gas emissions of approximately 2,117,929,000 kg CO2e. This includes 208,535,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 158,447,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. The majority of their emissions, about 1,750,947,000 kg CO2e, fall under Scope 3, which includes all other indirect emissions in the value chain. BMS has set ambitious climate commitments, aiming for net-zero emissions across all scopes by 2050. They have established near-term targets to reduce absolute Scope 1 and 2 emissions by 54.6% by 2033 from a 2022 baseline. Additionally, they plan to reduce Scope 3 emissions from fuel and energy-related activities by the same percentage within the same timeframe. By 2050, BMS aims to achieve a 90% reduction in absolute emissions across all scopes from the 2022 baseline. The company is also committed to ensuring that 75% of its suppliers, by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect BMS's commitment to addressing climate change comprehensively.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|
Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bristol-Myers Squibb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.